Introduction
============

Allergic rhinoconjunctivitis is a common allergic respiratory disorder caused by allergens such as grass or tree pollens and house dust mites. The prevalence of allergic rhinoconjunctivitis is increasing and is a major health issue worldwide. In Europe and the US, up to 20% of the adult population suffers from this condition.[@b1-ceor-4-253]--[@b4-ceor-4-253] Allergic rhinoconjunctivitis is associated with symptoms such as a runny, blocked and/or itchy nose, sneezing, a gritty feeling in the eyes, and red/itchy/watery eyes, has a considerable impact on quality of life, and indirect costs arising from absenteeism from work and school, impaired sleep quality, and decreased productivity.[@b5-ceor-4-253]--[@b9-ceor-4-253] Furthermore, allergic rhinoconjunctivitis is an independent risk factor for asthma or sinusitis.[@b5-ceor-4-253] This increases the societal and economic impact of allergic rhinoconjunctivitis.

Treatment strategies for allergic rhinoconjunctivitis are largely symptomatic, and include oral antihistamines, nasal corticosteroids, and eye drops.[@b10-ceor-4-253] However, the underlying allergic disease remains unaffected and symptomatic treatment offers only short-term relief.

Allergen-specific immunotherapy is the only treatment capable of activating immunomodulatory mechanisms and modifying the underlying course of the disease, thereby providing sustained relief of symptoms.[@b11-ceor-4-253] Allergen-specific immunotherapy can be administered in different formulations, such as subcutaneous immunotherapy (SCIT) and allergy immunotherapy tablets (AIT).

SCIT has been widely used throughout Europe for decades. Treatment is initiated by a uptitration phase, during which the patient is given subcutaneous injections with increasing doses of allergen over a period of several weeks. This is followed by a maintenance phase during which the patient is given the maximum tolerated dose of allergen with each injection. More recently, AIT, a new and convenient form of immunotherapy, has been approved and marketed. AIT can be self-administered at home without uptitration.

The magnitude of and similarity in efficacy between these two treatment concepts has been and is still widely discussed. SCIT is documented to be efficacious and well tolerated in patients with grass pollen-induced allergic rhinoconjunctivitis. [@b12-ceor-4-253] Sustained effectiveness of SCIT has also been demonstrated.[@b13-ceor-4-253] Several trials have likewise confirmed the benefits of AIT treatment, with sustained efficacy and a favorable safety profile in patients with grass pollen-induced allergic rhinoconjunctivitis.[@b14-ceor-4-253]--[@b21-ceor-4-253]

Direct comparisons between SCIT and AIT in clinical trials are still lacking, mainly because of the use of different treatment regimens and thereby difficulties in designing proper and ethical head-to-head comparisons. However, the efficacy of grass AIT and grass SCIT has recently been compared in a meta-analysis,[@b22-ceor-4-253] which concluded that the clinical effect of grass AIT is similar in magnitude to that observed for SCIT in patients with grass pollen-induced allergic rhinoconjunctivitis of the same severity.

The international economic crisis has led to an increased demand for evaluations of potential cost savings to health care systems without impacting the quality and safety of treatment, and budget impact analyses showing the economic consequences of different treatments may be highly relevant or even warranted for health care decision-makers. This study compared the economic consequences of treating patients with grass pollen-induced allergic rhinoconjunctivitis using either grass AIT or grass SCIT.

Materials and methods
=====================

Health economic analysis
------------------------

A model was constructed to compare the budget impact of two standard immunotherapy treatments, ie, SQ-standardized grass AIT (Grazax^®^; *Phleum pratense*, 75,000 SQ-T/2,800 BAU; ALK, Denmark) and grass SCIT (Alutard; *P. pratense*, 100,000 SQ-U; ALK, Denmark). The model was developed based on clinical data[@b21-ceor-4-253] and a recently published meta-analysis, [@b22-ceor-4-253] and all calculations were performed using Microsoft Office Excel 2007 (Microsoft, Redmond, WA).

The methodology for developing the budget impact analysis followed international health economic guidelines for budget impact analyses.[@b23-ceor-4-253] According to these guidelines, a budget impact analysis should define scenarios relevant to health care decision-makers, the perspective should be that of the budget-holder, and the outcome of the analysis should reflect scenarios of interest to the decision-maker rather than assumptions intended to be generally applicable. Therefore, our budget impact analysis included calculation of all marginal costs from a Danish health care perspective to estimate possible annual savings to health care budgets resulting from implementation of grass AIT instead of grass SCIT. The analysis also included patient and societal costs, and reported these costs separately.

General model assumptions
-------------------------

The economic evaluation was conducted from a Danish health care perspective and included allergy treatment for adults in both the primary and secondary sector in Denmark. The analysis included direct treatment costs (cost of medication and physician visits), direct patient costs (travel expenses), and indirect patient costs (time lost). In accordance with Danish guidelines,[@b24-ceor-4-253] a discount rate of 3% per year was applied to account for treatment duration of 3--5 years. General model assumptions are outlined in [Table 1](#t1-ceor-4-253){ref-type="table"}.

Resource use
------------

Resources in terms of medication use, physician visits, and patient time were calculated and are outlined in [Table 2](#t2-ceor-4-253){ref-type="table"}. Health care utilization was calculated based on data collected from a review of clinical trials and standard treatment in Denmark (according to the Summary of Product Characteristics), and where data were limited, these were validated by medical experts. Expert validation was obtained from two structured workshops with Danish physicians. The wide variability in the participating physicians' specialties is considered to contribute to the robustness of the analysis.

Costs
-----

Cost estimates are outlined in [Table 3](#t3-ceor-4-253){ref-type="table"}. Unit costs were obtained from established Danish public sources, including the Danish federal statistical office (Statistics Denmark), fees for service remuneration, and product list prices.[@b25-ceor-4-253]--[@b29-ceor-4-253] All costs are reported in 2010 prices except when otherwise stated. Costs were obtained in Danish kroner and exchanged to Euro using the average 2010 exchange rate (1 Euro = 7.447366 DKK).

Sensitivity analysis
--------------------

The robustness of the budget impact analysis was investigated using a one-way sensitivity analysis. The most sensitive resource costs were systematically calculated to investigate the sensitivity of the overall result. The sensitivity analysis was based on direct treatment costs.

Results
=======

Treatment-related costs
-----------------------

The result of the budget impact analysis is shown in [Table 4](#t4-ceor-4-253){ref-type="table"}. Direct treatment costs for treatment with grass SCIT were estimated to be €4555 per patient for a treatment course. In comparison, the direct treatment costs for treatment with grass AIT were estimated to be €3264 per patient for a treatment course, representing a cost saving of €1291 per patient. Estimated direct and indirect patients costs were €2694 for treatment with grass SCIT and €525 for treatment with grass AIT, representing a cost saving in total patient costs of €2169. Total savings (treatment costs and patient costs) amounted to €3460. This corresponds to a decrease of 28% in direct treatment costs, a decrease of 81% in direct and indirect patient costs, and a decrease in total costs of 48%, if treatment with grass AIT is used instead of grass SCIT ([Figure 1](#f1-ceor-4-253){ref-type="fig"}).

The cost savings gained by prescribing grass AIT instead of grass SCIT may be utilized to treat more patients with immunotherapy. In [Figure 2](#f2-ceor-4-253){ref-type="fig"}, the relationship is shown between the number of subjects treated with grass AIT instead of grass SCIT, cost savings when using grass AIT instead of grass SCIT, and the number of new patients who could possibly be started on grass AIT without any additional cost as compared with the current costs for grass SCIT. As shown, it is possible to treat a substantial number of new patients on grass AIT without any additional cost to the health care system. For example, if 1500 subjects were treated with grass AIT instead of grass SCIT, it would be possible to treat approximately 600 more patients per year without increasing the current costs to the health care system. This corresponds to an increase in the number of treated patients of approximately 40%.

Sensitivity analysis
--------------------

The results of the one-way sensitivity analysis are shown in [Table 5](#t5-ceor-4-253){ref-type="table"}. The basic treatment cost saving was €1291. Resource costs were varied in both directions and, regardless of variation/adjustment, all costs were in favor of grass AIT with incremental costs for grass SCIT. Notably, variations between the general practice and hospital settings resulted in major changes in direct treatment costs, whereas the discount rate and duration of treatment had no or at least less impact on the analysis.

Discussion
==========

A budget impact analysis compares the costs of different treatment options seen from a health care decision-maker perspective. Therefore, the focus of this budget impact analysis was to compare the economic consequences of treating patients with grass pollen-induced allergic rhinitis using either grass AIT or grass SCIT.

The analysis showed that overall direct treatment costs as well as patient costs were lower for treatment with grass AIT than for treatment with grass SCIT. The main cost difference between the two treatments was the result of fewer physician visits being needed for grass AIT as compared with grass SCIT. The cost of medication per patient was higher for grass AIT as compared with grass SCIT, whereas the costs of physician visits, travel expenses, and lost working hours were considerably lower for grass AIT. The overall impact was reduced costs for the health care system and society (reduced physician visits and resources) as well as for individual patients (reduced travel expenses and less lost working hours). The robustness of these results was confirmed by the one-way sensitivity analysis.

The total treatment cost saving to the health care system amounted to €1291 per patient per treatment course when using grass AIT instead of grass SCIT. In 2010, approximately 1200 patients were initiated on grass SCIT treatment in Denmark (data on file). Assuming a similar continuous number of patients initiating immunotherapy treatment per year in the future, the implication for Danish society will be a treatment cost saving of more than €1,500,000 on a yearly basis if grass AIT is used as treatment instead of grass SCIT. Cost saving in this range implies that more than 450 additional patients per year could be treated with grass AIT without influencing costs. An increase in the number of patients treated per year may have additional beneficial outcomes for the health care system both in terms of additional cost savings as well as in terms of improved health status for patients. Allergic rhinitis is an independent risk factor for development of asthma.[@b5-ceor-4-253] Because asthma is a disease with considerable burden and substantial costs to both the public and private health care systems,[@b30-ceor-4-253] the potential cost savings to the health care system may be even more pronounced if patients with grass pollen-induced allergic rhinitis are treated with grass immunotherapy. In addition, having more patients on immunotherapy may decrease the use of other kinds of medication used for treatment of allergic rhinitis and/or asthma, thereby decreasing costs to the health care system in relation to these medications. Grass AIT also has a number of other advantages which may be beneficial for the health care system, but which are not included in the budget impact analysis per se.

Grass AIT is generally considered to have a significantly lower risk profile than SCIT.[@b31-ceor-4-253],[@b32-ceor-4-253] The potentially lower costs for treatment of adverse events resulting from AIT are not considered in this analysis. The main cost related to side effects and seen from a health care decision-maker perspective is for hospitalization. Hospital admissions due to side effects of immunotherapy are considered to be uncommon but, because no firm documentation on the extent of these admissions is available, they have not been addressed in this study.

Treatment with grass AIT is also simpler and more convenient than for grass SCIT because tablets can be administered at home instead of injections at a clinic. Home administration will, as mentioned above, result in fewer physician visits as compared with grass SCIT, and thereby lead to cost savings to the health care system. However, home administration is often perceived to be related to lower compliance than that achieved when treatment is given in a specialist office, leading to lower efficacy of treatment. However, a recent study evaluating compliance with grass AIT and grass SCIT indicated that compliance with both treatments was high and comparable (≥80%).[@b33-ceor-4-253]

Grass AIT has also been shown to have a sustained and disease-modifying effect.[@b14-ceor-4-253],[@b21-ceor-4-253] This may lead to additional cost savings for both the individual patient and for society as a whole in terms of improved quality of life and lower costs related to absenteeism from work and decreased productivity.

Because several of the aforementioned factors are not included in the budget impact analysis due to limited data, a more comprehensive economic evaluation may be warranted to evaluate the overall health economic consequences of using grass AIT instead of grass SCIT. Further evaluation may include a cost-utility analysis to obtain data on quality of life for patients and a cost-benefit analysis to obtain data on willingness to pay.

Conclusion
==========

In conclusion, this budget impact analysis shows that grass AIT is a cost-saving alternative to grass SCIT when treating patients with grass pollen-induced allergic rhinitis. Seen from a health care perspective, grass AIT represents an efficient use of cost and resources. Further analyses may be warranted to evaluate the overall health economic consequences of implementation of grass AIT instead of grass SCIT.
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###### 

General model assumptions

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Overall assumptions                  Details
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Grass AIT**                        

  Duration of treatment                Patients are treated for 3 years according to Summary of Product Characteristics.

  Immunotherapy treatment and visits   Year 1: treatment is initiated by two consultations, ie, administration of first tablet in the clinic, and investigation of desired treatment effect approximately one month later. Initial consultations are followed by an additional follow-up consultation.\
                                       Years 2 and 3: two follow-up consultations per year.\
                                       In total, seven consultations per treatment course (3 years).

  Treatment setting                    Initiation of treatment takes place either at the general practitioner's office, at medical specialist in private clinic or at medical specialist in hospital setting. All follow-up consultations take place at the general practitioner's office.

  Additional medical supervision       No peak flow measurements are performed.

  Compliance                           Compliance is set to 80%.[a](#tfn2-ceor-4-253){ref-type="table-fn"}

  Package size                         Treatment is based on packs with 100 tablets and packs with 30 tablets.

  **Grass SCIT**                       

  Duration of treatment                Duration of treatment differs between hospitals (3 or 5 years). It is assumed that 80% of patients are treated for 3 years and 20% are treated for 5 years.

  Immunotherapy treatment and visits   Treatment is initiated with weekly injections at the clinic for 15 weeks (uptitration). This is followed by a transition phase with one injection 2 weeks after last uptitration injection and an additional injection 4 weeks after the first transition injection. Maintenance injections with 8 weeks interval. In total, 33 consultations in a 3-year treatment course; 47 consultations in a 5-year treatment course.

  Treatment setting                    Uptitration of treatment takes place at the general practitioner's office, at a medical specialist's private clinic or with a medical specialist in a hospital setting.\
                                       In the maintenance phase, 1/5 of patients uptitrated by a medical specialist are referred back to their own general practitioner. Treatment at medical specialists in private clinic is performed by internal medicine specialists, dermatologists, or ear, nose and throat specialists.

  Additional medical supervision       Peak flow measurements are performed before and after each injection.

  Compliance                           Compliance in uptitration phase is set to 100%. Compliance in maintenance phase is set to 90%.[a](#tfn2-ceor-4-253){ref-type="table-fn"}

  Vials                                Vials are personal and cannot be shared between patients. A maintenance vial (5 mL) contains 4.7 injections. All liquid in vials is used. If extra liquid is left after end of treatment, patients will receive extra injection at an additional visit.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Based on experiences from daily practice in Denmark.

**Abbreviations:** AIT, allergy immunotherapy tablets; SCIT, subcutaneous immunotherapy.

###### 

Resource use (health care utilization)

  Resource category   Resource type                                                                                           Year 1   Year 2   Year 3   Year 4   Year 5
  ------------------- ------------------------------------------------------------------------------------------------------- -------- -------- -------- -------- --------
  **Grass AIT**                                                                                                                                                   
  Medication          Number of tablets (tablet/day × compliance)[a](#tfn5-ceor-4-253){ref-type="table-fn"}                   292      292      292      --       --
  Physician           Number of initial visits (visit/year)[b](#tfn6-ceor-4-253){ref-type="table-fn"}                         2        --       --       --       --
                       Treatment by general practitioner                                                                      0.2      --       --       --       --
                       Treatment in private clinic                                                                            1.6      --       --       --       --
                       Treatment in hospital setting                                                                          0.2      --       --       --       --
                      Number of follow-up visits (visit/year)[c](#tfn7-ceor-4-253){ref-type="table-fn"}                       1        2        2        --       --
                       Treatment by general practitioner                                                                      1        2        2        --       --
                       Treatment in private clinic                                                                            --       --       --       --       --
                       Treatment in hospital setting                                                                          --       --       --       --       --
  Patient             Travel distance (km/visit)[d](#tfn8-ceor-4-253){ref-type="table-fn"}                                    30       20       20       --       --
                      Time lost (hours/visit)[e](#tfn9-ceor-4-253){ref-type="table-fn"}                                       6        4        4        --       --
  **Grass SCIT**                                                                                                                                                  
  Medication          Number of uptitration kits                                                                              1        --       --       --       --
                      Number of maintenance vials needed (actual)[f](#tfn10-ceor-4-253){ref-type="table-fn"}                  1.06     0.34     0.83     1.11     0.60
                      Number of maintenance vials needed (rounded)[g](#tfn11-ceor-4-253){ref-type="table-fn"}                 2        1        1        2        1
                      Remaining injections in opened vial at the end of the year[h](#tfn12-ceor-4-253){ref-type="table-fn"}   4.4      3.1      0.8      4.2      1.9
  Physician           Uptitration visits                                                                                      15       --       --       --       --
                      Maintenance visits                                                                                      5        6        7        6        8
                      Number of peak flow measurements[i](#tfn13-ceor-4-253){ref-type="table-fn"}                             10       12       14       12       16
  Patient             Travel distance (km/visit)[d](#tfn8-ceor-4-253){ref-type="table-fn"}                                    200      60       70       60       80
                      Time lost (hours/visit)[e](#tfn9-ceor-4-253){ref-type="table-fn"}                                       40       12       14       12       16

**Notes:**

One tablet/day; compliance = 80%;

two initial visits;

One follow-up visit 1st year; 2 follow-up visits the following years;

10 km/visit based on experiences from daily practice in Denmark;

2 hours/visit based on experiences from daily practice in Denmark;

number of maintenance visits (injections)/no of injections per maintenance vial; ie, no of maintenance visits (injections)/4.7;

number of maintenance vials rounded to nearest whole vial;

\[number of maintenance vial needed (rounded) -- number of maintenance vials (actual)\] × number of injections per maintenance vial. Remaining injections in opened vial at the end of the year are used in the following year;

peak flow measurements are performed before and after each injection. Peak flow measurements are included in medical specialist costs (private clinic/hospital setting), but not in general practice costs. Because general practitioners perform part of the maintenance visits, peak flow measurements are calculated based on number of maintenance visits.

**Abbreviations:** AIT, allergy immunotherapy tablets; SCIT, subcutaneous immunotherapy.

###### 

Cost input (in €)

  Cost category                                                                      Cost type                                                                    Unit              Cost/unit
  ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------- -----------
  **Medication**                                                                                                                                                                    
  Grass AIT                                                                          Pack with 30 tablets                                                         Per tablet        3.78
                                                                                     Pack with 100 tablets                                                        Per tablet        3.40
                                                                                     Average price, model assumption[a](#tfn16-ceor-4-253){ref-type="table-fn"}   Per tablet        3.48
  Grass SCIT                                                                         Uptitration kit                                                              Per uptitration   233.80
                                                                                     Maintenance                                                                  Per vial (5 mL)   224.40
  **Physician visits**                                                                                                                                                              
  General practitioners                                                              Visit                                                                        Per visit         17.38
                                                                                     Peak flow measurement                                                        Per measurement   4.87
  Medical specialists in private clinic[b](#tfn17-ceor-4-253){ref-type="table-fn"}   First visit                                                                  Per visit         78.86
                                                                                     Second visit                                                                 Per visit         52.43
                                                                                     Consecutive visit                                                            Per visit         19.34
                                                                                     First visit including fees[c](#tfn18-ceor-4-253){ref-type="table-fn"}        Per visit         113.49
                                                                                     Second visit including fees[c](#tfn18-ceor-4-253){ref-type="table-fn"}       Per visit         87.05
                                                                                     Consecutive visit including fees                                             Per visit         53.97
  Medical specialists in hospital setting                                            Outpatient visit                                                             Per visit         170.66
                                                                                     Additional costs, uncomplicated allergy treatment                            Per visit         384.03
                                                                                     Additional costs, complicated allergy treatment                              Per visit         528.11
  **Patient costs**                                                                                                                                                                 
  Work                                                                               Lost working hours[d](#tfn19-ceor-4-253){ref-type="table-fn"}                Per hour          36.16
  Travel                                                                             Travel by private car                                                        Per km            0.48

**Notes:** All costs are based on 2010 prices unless otherwise stated; medication costs[@b29-ceor-4-253] physician visit costs;[@b27-ceor-4-253],[@b28-ceor-4-253] patient costs.[@b25-ceor-4-253],[@b26-ceor-4-253]

Treatment based on packs with 100 tablets (80%) and pack with 30 tablets (20%);

medical specialist costs (private clinic) are based on a weighted average of consultation fees for internal medicine specialists, dermatologists and ear, nose and throat specialists;

fees include peak flow measurements and fee for injection;

lost working hours are based on the mean salary/hour for the general population aged 18--65 years in Denmark including the unemployed.

**Abbreviations:** AIT, allergy immunotherapy tablets; SCIT, subcutaneous immunotherapy.

###### 

Costs (in €) in relation to treatment with grass AIT and grass SCIT

  Cost category                              Resource type                      Year 1   Year 2   Year 3   Year 4   Year 5   Total
  ------------------------------------------ ---------------------------------- -------- -------- -------- -------- -------- -------
  **Grass AIT**                                                                                                              
  Direct treatment costs                     Medication (tablets)               1014     985      956      --       --       2955
                                             Physician visits                   242      34       33       --       --       309
                                              Treatment by GP                   21       34       33       --       --       88
                                              Treatment in private clinic       110      --       --       --       --       110
                                              Treatment in hospital setting     111      --       --       --       --       111
  Direct treatment costs, total                                                 1256     1019     989      --       --       3264
  Direct patient costs                       Travel expenses                    14       9        9        --       --       32
  Direct treatment + patient costs, total                                       1270     1028     998      --       --       3296
  Indirect costs                             Patient productivity (time lost)   217      140      136      --       --       493
  Total costs                                                                   1487     1168     1134     --       --       3789
  **Grass SCIT**                                                                                                             
  Direct treatment costs                     Medication (uptitration kits)      234      --       --       --       --       234
                                             Medication (maintenance vials)     449      218      212      82       40       1001
                                             Physician visits                   2027     504      571      95       123      3320
                                              Uptitration visits                1594     --       --       --       --       1594
                                              Maintenance visits                433      504      571      95       123      1726
  Direct treatment costs, total                                                 2710     722      783      177      163      4555
  Direct patient costs                       Travel expenses                    96       28       32       5        7        168
  Direct treatment + patient costs, total                                       2806     750      815      182      170      4723
  Indirect costs                             Patient productivity (time lost)   1446     421      477      79       103      2526
  Total costs                                                                   4252     1171     1,292    261      273      7249
  Cost reduction (grass AIT -- grass SCIT)                                      −2765    −3       −158     −261     −273     −3460

**Note:** Costs include 3% discount.

**Abbreviations:** AIT, allergy immunotherapy tablets; SCIT, subcutaneous immunotherapy.

###### 

One-way sensitivity analysis (direct treatment costs, in €)

  Sensitivity analysis                                                Mean direct treatment costs (€), grass AIT   Mean and incremental direct treatment costs (€), grass SCIT (difference from grass AIT)
  ------------------------------------------------------------------- -------------------------------------------- -----------------------------------------------------------------------------------------
  **General**                                                                                                      
  Base case                                                           3264                                         4555 (+1291)
  **Discount rate**                                                                                                
  0%                                                                  3354                                         4660 (+1306)
  5%                                                                  3207                                         4489 (+1282)
  **Grass AIT**                                                                                                    
  Base case                                                           3264                                         4555 (+1291)
  **Initiation of treatment**                                                                                      
  100% hospital setting                                               4148                                         4555 (+407)
  100% general practice                                               3074                                         4555 (+1480)
  **Follow-up treatment**                                                                                          
  As for grass SCIT                                                   3490                                         4555 (+1065)
  100% general practice                                               3264                                         4555 (+1291)
  **Number of visits/year**                                                                                        
  4 + 3 + 3                                                           3314                                         4555 (+1241)
  2 + 1 + 1                                                           3213                                         4555 (+1342)
  **Compliance**                                                                                                   
  100%                                                                4002                                         4555 (+553)
  60%                                                                 2525                                         4555 (+2030)
  **Duration of treatment**                                                                                        
  As for grass SCIT                                                   3688                                         4555 (+867)
  3 years                                                             3264                                         4555 (+1291)
  **Grass SCIT**                                                                                                   
  Base case                                                           3264                                         4555 (+1291)
  **Injections extracted per vial**                                                                                
  +20%                                                                3264                                         4515 (+1251)
  −20%                                                                3264                                         4836 (+1572)
  **Uptitration visits**                                                                                           
  100% hospital setting                                               3264                                         11,280 (+8016)
  100% general practice                                               3264                                         3366 (+102)
  **Maintenance visits**                                                                                           
  100% hospital setting                                               3264                                         13,891 (+10,627)
  100% general practice                                               3264                                         3369 (+105)
  **Number of weeks between injections**                                                                           
  10 weeks                                                            3264                                         3996 (+732)
  6 weeks                                                             3264                                         5301 (+2037)
  **Compliance, uptitration**                                                                                      
  100%                                                                3264                                         4555 (+1291)
  80%                                                                 3264                                         4250 (+986)
  **Compliance, maintenance**                                                                                      
  100%                                                                3264                                         4557 (+1293)
  70%                                                                 3264                                         4233 (+969)
  **Duration of treatment**                                                                                        
  0% treated for 5 years[a](#tfn24-ceor-4-253){ref-type="table-fn"}   3264                                         4214 (+950)
  40% treated for 5 years                                             3264                                         4894 (+1630)

**Note:**

All patients treated for 3 years.

**Abbreviations:** AIT, allergy immunotherapy tablets; SCIT, subcutaneous immunotherapy.
